• 1
    Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am. J. Pathol. 1949; 25; 647655.
  • 2
    Ishak KG, Anthony PP, Sobin LH. Histological typing of the liver. WHO International Histological Classification of Tumours, 2nd edn. Hong Kong: Springer-Verlag, 1994.
  • 3
    Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985; 55; 124135.
  • 4
    Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J. Gastroenterol. Hepatol. 1996; 11; 758764.
  • 5
    Libbrecht L. Hepatic progenitor cells in human liver tumor development. World J. Gastroenterol. 2006; 12; 62616265.
  • 6
    Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin. Liver Dis. 1999; 19; 243252.
  • 7
    Sell S. The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int. J. Dev. Biol. 1993; 37; 189201.
  • 8
    Roskams TA, Theise ND, Balabaud C et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39; 17391745.
  • 9
    Eleazar JA, Memeo L, Jhang JS et al. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J. Hepatol. 2004; 4l; 983991.
  • 10
    Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41; 809818.
  • 11
    Roskams T, De Vos R, Desmet V. ‘Undifferentiated progenitor cells’ in focal nodular hyperplasia of the liver. Histopathology 1996; 28; 291299.
  • 12
    Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin. Liver Dis. 2003; 23; 385396.
  • 13
    Haruna Y, Saito K, Spaulding S, Nalesnik MA, Gerber MA. Identification of bipotential progenitor cells in human liver development. Hepatology 1996; 23; 476481.
  • 14
    Evarts RP, Nagy P, Nakatsukasa H, Marsden E, Thorgeirsson SS. In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res. 1989; 49; 15411547.
  • 15
    Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep Par 1 and selected antibodies in the immunohistologic distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumors and metastatic carcinoma. Histopathology 1998; 33; 318324.
  • 16
    Paku S, Schnur J, Nagy P, Thorgeirsson SS. Origin and structural evolution of the early proliferating oval cells in rat liver. Am. J. Pathol. 2001; 158; 13131323.
  • 17
    Crosby HA, Hubscher SG, Joplin RE, Kelly DA, Strain AJ. Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. Hepatology 1998; 28; 980985.
  • 18
    Crosby HA, Kelly DA, Strain AJ. Human hepatic stem-like cells isolated using c-kit or CD34 can differentiate into biliary epithelium. Gastroenterology 2001; 120; 534544.
  • 19
    Bordoni V, Alonzi T, Zanetta L et al. Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. Hepatology 2007; 45; 12181228.
  • 20
    Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J. Hepatol. 1998; 29; 455463.
  • 21
    Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J. Gastroenterol. Hepatol. 1998; 13; 3440.
  • 22
    Aoki K, Takayasu K, Kawano T et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology 1993; 18; 10901095.
  • 23
    Liu CL, Fan ST, Lo CM et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch. Surg. 2003; 138; 8690.
  • 24
    The Liver Cancer Study Group of Japan. Fourteenth National Primary Liver Cancer Tracking Survey Report (1996–1997) (in Japanese). Kyoto: Shinkou Printed, 2000.
  • 25
    Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF. Long-term outcome of resection of large hepatocellular carcinoma. Br. J. Surg. 2006; 93; 600606.
  • 26
    Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am. J. Surg. Pathol. 2002; 26; 978988.
  • 27
    Uenishi T, Kubo S, Yamamoto T et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003; 94; 851857.
  • 28
    Durnez A, Verslype C, Nevens F et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49; 138151.
  • 29
    Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25; 38183822.
  • 30
    Petersen BE, Bowen WC, Patrene KD et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284; 11681170.
  • 31
    Theise ND, Nimmakayalu M, Gardner R et al. Liver from bone marrow in humans. Hepatology 2000; 32; 1116.
  • 32
    Baumann U, Crosby HA, Ramani P, Kelly DA, Strain AJ. Expression of stem cell receptor c-kit in normal and diseased pediatric liver. Hepatology 1999; 30; 112117.
  • 33
    Thorgeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 2006; 43; 28.
  • 34
    Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O’Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab. Invest. 1998; 78; 16331636.
  • 35
    ZTonary AM, Macdonald EA, Faught W, Senterman MK, Vanderhyden BC. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int. J. Cancer 2000; 89; 242250.
  • 36
    Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004; 15; 405409.
  • 37
    Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T. Hepatic progenitor cells in hepatocellular adenomas. Am. J. Surg. Pathol. 2001; 25; 13881396.
  • 38
    Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J. Hepatol. 2000; 33; 7684.
  • 39
    Van Den Heuvel MC, Slooff MJ, Visser L et al. Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary line of normal and diseased human livers. Hepatology 2001; 33; 13871393.
  • 40
    Alison MR. Characterization of the differentiation capacity of rat-derived hepatic stem cells. Semin. Liver Dis. 2003; 23; 325336.
  • 41
    Tanaka S, Hirohashi K, Uenishi T et al. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker. Hepatogastroenterology 2004; 51; 839841.
  • 42
    Yano H, Iemura A, Haramaki M et al. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J. Hepatol. 1996; 24; 413422.
  • 43
    Wiemann SU, Satyanarayan A, Tsahuridu M et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002; 16; 935942.
  • 44
    Wiemann SU, Satyanarayan A, Buer J, Kamino K, Manns MP, Rudolph KL. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. Oncogene 2005; 249; 15011509.